Back

Prevalence and outcomes of prasugrel versus clopidogrel in patients with and without diabetes following percutaneous coronary intervention for acute coronary syndrome

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 2 - Clinical platelet studies Thrombosis and platelets ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Michela Faggioni

Hospital of the University of Pennsylvania, Philadelphia (United States of America)

24 More presentations in this session

Presentation thumbnail
Effect of pretreatment with P2Y12 receptor antagonists on mortality in patients undergoing PCI: A report from SCAAR
Professor E. Omerovic (Gothenburg, SE)
Abstract
Presentation thumbnail
Gender differences in oral antiplatelet treatment use - results from a nationwide cohort study of acute coronary syndrome patients in Finland
Doctor V. Kyto (Turku, FI)
Abstract Slides
Presentation thumbnail
Platelet reactivity and outcomes after transcatheter aortic valve implantation
Doctor L. Gross (Munich, DE)
Abstract Slides
Presentation thumbnail
Safety of a regional standardized protocol to optimize the use of most effective platelet inhibition in ACS treated with PCI : Final Results from the Multicenter Rijnmond Collective Cardiology Study
Doctor M. Van Der Linden (Schiedam, NL)
Abstract Slides
Presentation thumbnail
Characteristics and safety outcomes in first-time users of the P2Y12 receptor antagonists clopidogrel, prasugrel and ticagrelor
Associate Professor S. Johansson (Molndal, SE)
Abstract Slides

Access the full session

Session thumbnail
Poster session 2 - Clinical platelet studies

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources